Co Diagnostics Net Worth
Co Diagnostics Net Worth Breakdown | CODX |
Co Diagnostics Net Worth Analysis
Co Diagnostics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Co Diagnostics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Co Diagnostics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Co Diagnostics' net worth analysis. One common approach is to calculate Co Diagnostics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Co Diagnostics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Co Diagnostics' net worth. This approach calculates the present value of Co Diagnostics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Co Diagnostics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Co Diagnostics' net worth. This involves comparing Co Diagnostics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Co Diagnostics' net worth relative to its peers.
Enterprise Value |
|
To determine if Co Diagnostics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Co Diagnostics' net worth research are outlined below:
| Co Diagnostics generated a negative expected return over the last 90 days | |
| Co Diagnostics has some characteristics of a very speculative penny stock | |
| Co Diagnostics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 6.81 M. Net Loss for the year was (35.33 M) with profit before overhead, payroll, taxes, and interest of 28.74 M. | |
| Co Diagnostics currently holds about 86.49 M in cash with (22.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Co Diagnostics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility |
Co Diagnostics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Co Diagnostics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Co Diagnostics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Co Diagnostics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Co Diagnostics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Co Diagnostics backward and forwards among themselves. Co Diagnostics' institutional investor refers to the entity that pools money to purchase Co Diagnostics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Thompson Davis & Co Inc | 2024-09-30 | 41.5 K | Group One Trading, Lp | 2024-09-30 | 40.1 K | Uma Financial Services Inc | 2024-09-30 | 28.4 K | Smi Advisory Services Llc | 2024-09-30 | 28 K | Virtu Financial Llc | 2024-06-30 | 27.9 K | Citadel Advisors Llc | 2024-09-30 | 25.4 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 14.5 K | Ubs Group Ag | 2024-09-30 | 12.8 K | Advisor Group Holdings, Inc. | 2024-09-30 | 12.4 K | Vanguard Group Inc | 2024-09-30 | 1.8 M | Renaissance Technologies Corp | 2024-09-30 | 567.7 K |
Follow Co Diagnostics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 23.16 M.Market Cap |
|
Project Co Diagnostics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.51) | (0.54) | |
| Return On Capital Employed | (0.48) | (0.45) | |
| Return On Assets | (0.37) | (0.39) | |
| Return On Equity | (0.41) | (0.43) |
When accessing Co Diagnostics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Co Diagnostics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Co Diagnostics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Co Diagnostics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Co Diagnostics. Check Co Diagnostics' Beneish M Score to see the likelihood of Co Diagnostics' management manipulating its earnings.
Evaluate Co Diagnostics' management efficiency
Co Diagnostics has return on total asset (ROA) of (0.2761) % which means that it has lost $0.2761 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5057) %, meaning that it created substantial loss on money invested by shareholders. Co Diagnostics' management efficiency ratios could be used to measure how well Co Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.54 in 2024. Return On Capital Employed is likely to rise to -0.45 in 2024. At this time, Co Diagnostics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 34.8 M in 2024, whereas Total Assets are likely to drop slightly above 50.6 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.93 | 3.08 | |
| Tangible Book Value Per Share | 2.03 | 2.13 | |
| Enterprise Value Over EBITDA | (0.65) | (0.69) | |
| Price Book Value Ratio | 0.45 | 0.43 | |
| Enterprise Value Multiple | (0.65) | (0.69) | |
| Price Fair Value | 0.45 | 0.43 | |
| Enterprise Value | 27.1 M | 25.7 M |
Management at Co Diagnostics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue 0.0639 | Revenue 7.3 M | Quarterly Revenue Growth (0.74) | Revenue Per Share 0.244 | Return On Equity (0.51) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Co Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Co Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Co Diagnostics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Co Diagnostics time-series forecasting models is one of many Co Diagnostics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Co Diagnostics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Co Diagnostics Earnings per Share Projection vs Actual
Co Diagnostics Corporate Management
| Christopher Thurston | Chief Officer | Profile | |
| Andrew Benson | Head Relations | Profile | |
| Mayuranki Almaula | Senior Alliances | Profile | |
| Dan CPA | Vice Accounting | Profile | |
| Ivory Chang | Chief Officer | Profile |
Additional Tools for CODX Stock Analysis
When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.